New York's attorney general has launched an antitrust lawsuit against Actavis, accusing it of illegally trying to switch customers from a drug to treat Alzheimer’s disease, the patent on which expires soon, to a new drug in order to avoid competition from generic firms
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
National groups for the UK and the Netherlands have flagged concerns with the choice of venue, following a formal complaint from Australia’s national group